Document is current
Any future updates will be listed below
-
Authors
Janssen, Saskia https://orcid.org/0000-0003-0966-3233
Vongjarudech, Thanakorn
Karlsson, Mats O.
Upton, Caryn M.
Garcia-Prats, Anthony J.
Diacon, Andreas H.
Wiesner, Lubbe
Sachs, Tina
van der Laan, Louvina E.
Salazar-Austin, Nicole
Hesseling, Anneke C.
Svensson, Elin M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
pactr202306775627089 at Pan African Clinical Trial RegistryDocuments that mention this clinical trial
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
https://doi.org/10.1007/s40262-025-01576-3
-
Funding
Funding for this research was provided by:
UNITAID (2017-20-IMPAACT4TB)
Stellenbosch University
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 2 September 2025
First Online: 11 October 2025
Declarations
:
: This study was funded by UNITAID through the IMPACT4TB project grant 2017-20-IMPAACT4TB awarded to Aurum.
: Elin M. Svensson is an Editorial Board member of Clinical Pharmacokinetics but was not involved in the selection of peer reviewers or in any subsequent editorial decisions related to this manuscript. The other authors declare no competing interests.
: The study was approved by the Stellenbosch University Health Research Ethics Committee (reference number 26169), the South African Health Products Regulatory Authority (Trial Reference 20220905) and the WHO Ethical Review Committee (Reference ERC.0003837) prior to initiation. The trial is registered with the Pan African Clinical Trials Registry (PACTR202306775627089).
: All adults provided written informed consent in the home language of their choice prior to their inclusion in the studies. No personally identifiable information is presented in this article.
: All participants provided consent for publication
: Data will be made available upon reasonable request to the corresponding author.
: The code used for the final model is provided in ESM S2 for the rifapentine model and in ESM S3 for the isoniazid model.
: S. Janssens coordinated the study, contributed to the study design, and drafted the manuscript. T. Vongjarudech was responsible for conducting the modelling and analysis and contributed to drafting the manuscript. A.C. Hessling and E.M. Svensson contributed to the study design and analysis and provided supervision. All authors have approved the final manuscript.
